Pulished Date October, 2018
ID: 834
Share on
Share on

North America Lung Cancer Therapeutics Market By Treatment Type (Chemotherapy (Cisplatin, Taxol, Navelbine, Camptosar And Alimta), Radiotherapy (External Beam, Internal Beam And Systemic) And Other Drugs (Abraxane, Avastin, Crizotinib, Docetaxel And Gefitinib)) And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018-2023)

Pulished: October, 2018
ID: 834
Pages: 145

Overview of the Market:
The North America Lung Cancer Therapeutics Market was worth $2.06 billion in 2018 and estimated to be growing at a CAGR of 6.14%, to reach $2.7 billion by 2023. North America led the overall market in 2016 and was closely followed by Asia Pacific.

Lung cancer is a malignant lung carcinoma which is characterized by irregular cell growth in lung tissue. As the tumour grows in size, it reduces the lungs’ ability to provide oxygen to arteries, veins and capillaries. Lung cancer has extreme mortality rate all over the region and the leading reason embraces of cigarette smoking. Cures of lung cancer include chemotherapy and radiation therapy.

Lung cancer therapeutics market displays favourable CAGR due to growing population of lung cancer and it is predicted that drift would continue with the same pace. The promising drivers for lung cancer therapeutic market are tobacco smoking, elderly population and irregular lifestyle. Conversely, high unmet need for diagnosis, accessibility of great number of generic forms of major drugs and inadequate treatment options are the key restrains to the North America lung cancer therapeutics market.

The North America Lung Cancer Therapeutics Market is segmented on the basis of treatment type nto Chemotherapy, Radiotherapy and Other Drugs. Based on drug type, Lung Cancer Chemotherapy market is segmented into cisplatin, taxol, navelbine, camptosar and Alimta. Based on type, Lung Cancer Radiotherapy market is segregated into external beam, internal beam and systemic. On the basis of drug type, Other Lung Cancer Therapeutic Drugs market is segmented into abraxane, avastin, crizotinib, docetaxel and Gefitinib. The top global brands that are commercially accessible in the market are Avastin, Alimta and taxol. Radiotherapy accounts for the largest segment in the lung cancer therapeutics market.

Geographical Analysis: 
Based on geography the market is analysed under various regions namely, USA and Canada. USA is the dominating country for lung cancer therapeutics market in terms of revenue followed by Canada.

Key Players in this Market: 
Companies are implementing various strategies to increase their product portfolio and rise its geographical presence. New product expansion, contracts and associations and procurements are some of the significant approaches adopted by the manufacturers in the lung cancer therapeutics market. The prominent players of this market include BoehringerIngelheim GmbH, Hoffman-La Roche, Pfizer Inc., GlaxoSmitKline, Eli Lilly and Company, Agennix AG, AstrazenecaPlc, and Sanofi-Aventis.

1. Introduction                                                 

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                           

                1.4 General Study Assumptions                                

2. Research Methodology                                                           

                2.1 Introduction                                              

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                            

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                     

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

3. Overview                                                      

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                      

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                               

5. Market Segmentation                                                              

                5.1 By Treatment Type                                 

                                5.1.1 Chemotherapy                     

                                                5.1.1.1 Cisplatin

                                                5.1.1.2 Taxol      

                                                5.1.1.3 Navelbine            

                                                5.1.1.4 Camptosar          

                                                5.1.1.5 Alimta   

                                5.1.2 Radiotherapy                         

                                                5.1.2.1 External Beam   

                                                5.1.2.2 Internal Beam    

                                                5.1.2.3 Systemic              

                                5.1.3 Other Drugs                            

                                                5.1.3.1 Abraxane             

                                                5.1.3.2 Avastin 

                                                5.1.3.3 Crizotinib             

                                                5.1.3.4 Docetaxel            

                                                5.1.3.5 Gefitinib               

6. Geographical Analysis                                                              

                6.1 Introduction                                              

                6.2 United States                                            

                6.3 Canada                                         

7. Pipeline Product Analysis                                                       

                7.1 Overview                                                    

                7.2 Pipeline Development Landscape                                                    

                7.3 Molecular Targets in the Pipeline                                                     

                7.4 Clinical Trials                                             

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target                       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                                  

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.                               

8. Strategic Analysis                                                       

                8.1 PESTLE analysis                                         

                                8.1.1 Political                     

                                8.1.2 Economic                 

                                8.1.3 Social                         

                                8.1.4 Technological                         

                                8.1.5 Legal                          

                                8.1.6 Environmental                      

                8.2 Porter’s Five analysis                                              

                                8.2.1 Bargaining Power of Suppliers                        

                                8.2.2 Bargaining Power of Consumers                    

                                8.2.3 Threat of New Entrants                     

                                8.2.4 Threat of Substitute Products and Services               

                                8.2.5 Competitive Rivalry within the Industry                      

9. Market Leaders' Analysis                                                        

                9.1 BoehringerIngelheim GmbH                               

                                9.1.1 Overview                

                                9.1.2 Product Analysis                   

                                9.1.3 Strategic Evaluation and Operations                            

                                9.1.4 Financial analysis                  

                                9.1.5 Legal issues                            

                                9.1.6 Recent Developments                       

                                9.1.7 SWOT analysis                       

                                9.1.8 Analyst View                          

                9.2 Hoffman-La Roche                                  

                9.3 Pfizer Inc.                                    

                9.4 GlaxoSmitKline                                         

                9.5 Eli Lilly and Company                                             

                9.6 AstrazenecaPlc                                         

                9.7 Sanofi-Aventis                                          

                9.8 Agennix AG                                

10. Competitive Landscape                                                         

                10.1 Market share analysis                                          

                10.2 Merger and Acquisition Analysis                                     

                10.3 Agreements, collaborations and Joint Ventures                                       

                10.4 New Product Launches                                       

11. Expert Opinions                                                        

                11.1 Market Outlook                                     

                11.2 Investment Opportunities                                 

Appendix                                                           

                a) List of Tables                                

                b) List of Figures                                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Lung Cancer Therapeutics Market By Region, From 2018-2023 (USD Billion)
  2. North America Lung Cancer Therapeutics Market By Treatment Type, From 2018-2023 (USD Billion)
  3. North America Chemotherapy Market By Region, From 2018-2023 (USD Billion)
  4. North America Radiotherapy Market By Region, From 2018-2023 (USD Billion)
  5. North America Other Lung Cancer Therapeutic Drugs Market By Region, From 2018-2023 (USD Billion)
  6. United States Lung Cancer Therapeutics Market By Treatment Type, From 2018-2023 (USD Billion)
  7. Canada Lung Cancer Therapeutics Market By Treatment Type, From 2018-2023 (USD Billion)
  8. North America Lung Cancer Chemotherapy Market By Drug Type, From 2018-2023 (USD Billion)
  9. North America Cisplatin Market By Region, From 2018-2023 (USD Billion)
  10. North America Taxol Market By Region, From 2018-2023 (USD Billion)
  11. North America Navelbine Market By Region, From 2018-2023 (USD Billion)
  12. North America Camptosar Market By Region, From 2018-2023 (USD Billion)
  13. North America Alimta Market By Region, From 2018-2023 (USD Billion)
  14. United States Lung Cancer Chemotherapy Market By Drug Type, From 2018-2023 (USD Billion)
  15. Canada Lung Cancer Chemotherapy Market By Drug Type, From 2018-2023 (USD Billion)
  16. North America Lung Cancer Radiotherapy Market By Type, From 2018-2023 (USD Billion)
  17. North America External Beam Market By Region, From 2018-2023 (USD Billion)
  18. North America Internal Beam Market By Region, From 2018-2023 (USD Billion)
  19. North America Systemic Market By Region, From 2018-2023 (USD Billion)
  20. United States Lung Cancer Radiotherapy Market By Type, From 2018-2023 (USD Billion)
  21. Canada Lung Cancer Radiotherapy Market By Type, From 2018-2023 (USD Billion)
  22. North America Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2018-2023 (USD Billion)
  23. North America Abraxane Market By Region, From 2018-2023 (USD Billion)
  24. North America Avastin Market By Region, From 2018-2023 (USD Billion)
  25. North America Crizotinib Market By Region, From 2018-2023 (USD Billion)
  26. North America Docetaxel Market By Region, From 2018-2023 (USD Billion)
  27. North America Gefitinib Market By Region, From 2018-2023 (USD Billion)
  28. United States Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2018-2023 (USD Billion)
  29. Canada Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2018-2023 (USD Billion)

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients